
Kidney injuries on Ozempic
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
drug:orforglipron
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
chemical:semaglutide
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
category:news
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
category:news
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
drug:eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
company:roche
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
category:news
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
malady:addiction
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.